Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2551 to 2560 of 2610 total matches.

Measles Revaccination

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989  (Issue 797)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
In the first six months of 1989, more than 7,000 cases of measles were reported to the US Centers for Disease Control (CDC), a sharp increase over previous years (Morbid Mortal Weekly Rep, 33:456, July 7, 1989). Many of these cases occurred in children and college students who had previously been vaccinated against the disease. Practitioners have asked, therefore, whether their previously immunized young patients should receive a second (or, in some cases, third) immunization against measles.
Med Lett Drugs Ther. 1989 Jul 28;31(797):69-70 |  Show IntroductionHide Introduction

The Reflotron For Office Chemistry

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The Reflotron (Boehringer Mannheim), a desk-top colorimetric reflectance analyzer that weighs 12 pounds, can do clinical chemistry tests on 30 l of whole blood, plasma or serum, using multilayered strips containing dry chemicals. A single test takes two to three minutes.
Med Lett Drugs Ther. 1989 Oct 6;31(802):90-1 |  Show IntroductionHide Introduction

Peripheral-Blood Stem-Cells Transplants

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
High-dose chemotherapy, with or without total body radiation, followed by bone marrow transplantation to restore bone marrow function has been used widely in the treatment of malignant diseases in recent years (Medical Letter, 34:79, 1992; 37:25, 1995). Now, however, instead of using bone marrow itself to restore function destroyed by chemotherapy and radiation, many centers infuse hematopoietic stem cells harvested from peripheral blood. Most stem cell transplants have been autologous; allogeneic stem cells have been tried in a small number of patients (WI Bensinger et al, Blood,...
Med Lett Drugs Ther. 1995 Aug 18;37(955):71-2 |  Show IntroductionHide Introduction

Spinal Manipulation

   
The Medical Letter on Drugs and Therapeutics • May 27, 2002  (Issue 1131)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Spinal manipulation has been used to treat not only back and neck pain, but also many other conditions. A recent commentary questioned its safety.
Med Lett Drugs Ther. 2002 May 27;44(1131):50 |  Show IntroductionHide Introduction

Lp-PLA2: a New Marker of Vascular Risk

   
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003  (Issue 1167)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to measure Lp-PLA2 levels. C-reactive protein (CRP), another inflammatory mediator, appears to be a biomarker for coronary disease (MH Shishehbor et al, Cleve Clin J Med 2003; 70:634). The role of Lp-PLA2 testing in determining cardiovascular risk is less clear.
Med Lett Drugs Ther. 2003 Oct 13;45(1167):83-4 |  Show IntroductionHide Introduction

COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
. Accessed July 2, 2025. 5. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National ...
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe outcomes from COVID-19. Spikevax, the original Moderna mRNA COVID-19 vaccine, remains in production2; it is licensed for use in persons ≥12 years old and is available under an Emergency Use Authorization (EUA) for children 6 months to 11 years old.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):119-20   doi:10.58347/tml.2025.1733h |  Show IntroductionHide Introduction

Penbraya: A Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy. The Medical Letter ® Vol. 66 ...
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo, MenQuadfi) and two meningococcal serogroup B vaccines (MenB; Bexsero, Trumenba) are available in the US (see Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5   doi:10.58347/tml.2024.1698b |  Show IntroductionHide Introduction

Penmenvy — A Second Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
on immunization practices ― United States, 2023. MMWR Morb Mortal Wkly Rep 2024; 73:345. 6. Drugs and Lactation ...
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):57-9   doi:10.58347/tml.2025.1726a |  Show IntroductionHide Introduction

Formula Diets for Obesity

   
The Medical Letter on Drugs and Therapeutics • Mar 10, 1989  (Issue 787)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Liquid diets for weight reduction, once discredited because of their adverse effects, are becoming popular again. Now, formula diets are available through physicians or hospitals as part of a packaged weight-reduction program that includes nutrition education and modification of eating and exercise habits. Three widely used programs are Optifast (Sandoz), Medifast (Nutrition Institute of Maryland, 1840 York Road, Timonium, MD 21093) and HMR (Health Management Resources, 59 Temple Place, Boston, MA 02111).
Med Lett Drugs Ther. 1989 Mar 10;31(787):22-3 |  Show IntroductionHide Introduction

Insect Venom Immunotherapy

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993  (Issue 900)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Systemic allergic reactions to insect stings can include generalized urticaria, bronchospasm, laryngeal edema, hypotension and death. About 1% to 3% of adults in the USA have had a systemic allergic reaction to an insect sting (RE Reisman, Med Clin North Am, 76:883, 1992; UR M ller, Monogr Allergy, 31:131, 1993).
Med Lett Drugs Ther. 1993 Jul 9;35(900):63-4 |  Show IntroductionHide Introduction